A report about a recent study documenting the impact of the pharmaceutical industry on medical education courses finds biased drug promotion for binge eating disorder.
New research published in the Journal of the American Board of Family Medicine finds industry bias promoting the drug lisdexamfetamine (brand name Vyvanse) in continuing medical education (CME) for health professionals. Lisdexamfetamine is the first Food and Drug Administration (FDA) approved drug for binge eating disorder (BED).
This study was conducted by Jinhyun Jung and Adriane Fugh-Berman of the University of North Carolina (see MIA interview with Fugh-Berman here). As BED is a controversial diagnosis, the researchers wanted to study if the pharmaceutical industry-sponsored CMEs were helping to promote the legitimacy of binge eating disorder. Their analysis of CME modules found extensive industry influence and presentations that routinely exaggerated the benefits and underreported the adverse effects of lisdexamfetamine.